Physician profile
Christopher D Wright
NPI 1043207426
$2,763.44
in general payments reported to CMS, 2019-2025
19 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $53.07 · 2021: $161 · 2022: $566 · 2023: $603 · 2024: $735 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $664.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $424.65 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $364.56 | 2019-2025 | Vraylar, Synthroid, Ubrelvy |
| Glaxosmithkline, LLC. | $240.70 | 2021-2025 | Shingrix, Arexvy |
| Pfizer INC. | $197.64 | 2022-2025 | |
| Amgen INC. | $185.77 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $182.45 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Boston Scientific Corporation | $149.45 | 2024 | Resolution 360 Clip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.94 | 2022-2024 | Xifaxan |
| Noven Therapeutics, LLC | $76.98 | 2023-2024 | Xelstrym |
| Astrazeneca Pharmaceuticals Lp | $48.26 | 2023-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $33.61 | 2019-2020 | |
| Ibsa Pharma INC. | $23.79 | 2025 | Tirosint, Licart, Flector |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.90 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $15.58 | 2022 | |
| Amarin Pharma, INC. | $15.14 | 2020 | |
| Esperion Therapeutics, INC. | $14.51 | 2025 | Nexletol |
| Zyla Life Sciences, INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.